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Abstract
Background: The present study was prompted by the 
ISO 15189 requirements that medical laboratories should 
estimate measurement uncertainty (MU).
Methods: The method used to estimate MU included the: 
a) identification of quantitative tests, b) classification of 
tests in relation to their clinical purpose, and c) identifica-
tion of criteria to estimate the different MU components. 
Imprecision was estimated using long-term internal 
quality control (IQC) results of the year 2016, while exter-
nal quality assessment schemes (EQAs) results obtained 
in the period 2015–2016  were used to estimate bias and 
bias uncertainty.
Results: A total of 263  measurement procedures (MPs) 
were analyzed. On the basis of test purpose, in 51 MPs 
imprecision only was used to estimate MU; in the remain-
ing MPs, the bias component was not estimable for 22 MPs 
because EQAs results did not provide reliable statistics. 
For a total of 28 MPs, two or more MU values were calcu-
lated on the basis of analyte concentration levels. Overall, 
results showed that uncertainty of bias is a minor factor 
contributing to MU, the bias component being the most 
relevant contributor to all the studied sample matrices.
Conclusions: The model chosen for MU estimation 
allowed us to derive a standardized approach for bias 
calculation, with respect to the fitness-for-purpose of 
test results. Measurement uncertainty estimation could 
readily be implemented in medical laboratories as a use-
ful tool in monitoring the analytical quality of test results 
since they are calculated using a combination of both the 
long-term imprecision IQC results and bias, on the basis 
of EQAs results.
Keywords: external quality assessment schemes (EQAs); 
internal quality controls (IQC); ISO 15189; measure-
ment procedures (MPs); measurement uncertainty (MU); 
medical laboratory accreditation.
Introduction
Medical laboratory results are widely recognized as a tool 
of fundamental importance in making a reliable diagnosis, 
monitoring diseases and providing information conducive 
to clinical decision-making. However, medical laborato-
ries should guarantee that their measurement procedures 
(MPs) results are fit for clinical purposes, and this require-
ment calls for the long-term monitoring of the quality and 
reliability of results. Since its inception, the International 
Standard ISO 15189 for medical laboratory accreditation 
has called for the calculation of measurement uncertainty 
(MU) to be included in each MP [1]. Interestingly, because 
MPs are used to describe the whole measurement process, 
including the specific analytical procedure, all processes 
which contribute to uncertainty in the test results should 
be considered when calculating MU. The international 
vocabulary of metrology (VIM) has defined MU as a “non-
negative quantity that characterizes the dispersion of the 
values that could reasonably be attributed to the measur-
and” [2]. For a given test result, MU thus represents the 
interval associated with a defined probability in which 
the true result should lie. In addition, this interval should 
fall within limits which guarantee fitness for the clini-
cal purpose of the tests in question [3, 4]. Measurement 
uncertainty goals for defining fitness-for-purpose limits 
may be based on clinical outcome studies, biological vari-
ation, state of the art, recommendations from an expert 
group or professional opinions [5, 6].
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The components which require consideration in 
calculating MU are systematic error (bias) and random 
errors. Bias is inversely related to the degree of trueness of 
a measurement, while random error represents impreci-
sion and is defined as the standard deviation of a series of 
measurements [6]. In contrast to the Guide to the Expres-
sion of Uncertainty in Measurement model (GUM) [7], 
which recommends the identification and elimination of 
bias at an early stage of the measurement process, the 
Westgard “total error approach” includes both an impre-
cision and bias component [8]. As discussed by Farrance 
et al. [9], either procedure may be used to evaluate MU as 
ISO 15189 does not specify any particular approach. In 
either situation, however, the true value of the measurand 
cannot be known, as uncertainty associated with deter-
mining bias, in addition to assay imprecision, provide 
uncertainty as to the true value. In a similar situation 
to assay imprecision, true bias cannot be determined: 
whether determined using a reference method or derived 
from an external quality assessment scheme (EQAs), there 
will always be an uncertainty associated with this deter-
mination. For example, in certified reference materials 
(CRM) the measurand concentration is associated with an 
MU, the value being given with the CRM as the best esti-
mate of the “true” level. In contrast, if bias is referred to 
the target value derived from EQA results (or a consensus 
value), it is calculated using the statistics which provide 
the distribution of results (with or without the use of refer-
ence methods or reference materials).
Depending on the test purpose, it might also be 
important to consider different models for calculating 
MU [4, 9, 10]. If the interpretation of a specific test result 
is largely provided by making a comparison with, e.g. 1) 
previous results from the same patient or 2) a reference 
interval established in the same laboratory or with the 
same MP, bias becomes largely irrelevant and MU in this 
setting concerns only the imprecision of the assay [9]. On 
the other hand, when the comparison is made with a clini-
cal decision point, the bias should be considered in the 
MU estimation when the clinical decision limits have been 
derived from multiple MPs [9, 10].
ISO 15189 allows flexibility for laboratories, stating 
that the “laboratory shall define the performance require-
ments for the MU of each MP and regularly review esti-
mates of MU”. Furthermore, several guidelines and 
manuscripts available in the literature propose different 
theoretical approaches for MU estimation [7, 11–14].
The aim of the present study was to describe an 
approach for estimating the MU for a large number of tests 
in medical laboratories and report the results obtained. In 
particular, the contributions of imprecision, bias and bias 
uncertainty, related to the overall MU were inspected and 
compared.
Materials and methods
The study was performed at the Department of Laboratory Medicine, 
University-Hospital of Padova in the year 2016.
Initially, the method used for estimating MU included the iden-
tification of:
 – quantitative tests, performed using both already approved/vali-
dated methods (i.e. CE-IVD) and “in house” validated methods;
 – classification for tests in relation to their main clinical purpose, 
diagnosis and/or monitoring;
 – criteria for estimating the different components of MU (bias, 
imprecision, bias uncertainty).
Measurement uncertainty components were calculated by using the 
formula suggested by NordTest [12] (Equation 3), which includes 
the: 1) imprecision component, calculated by the long term stand-
ard deviation of the internal quality controls (IQC) materials; 2) bias 
component, expressed as root mean square error of bias, calculated 
using the last eight EQAs exercises; 3) bias uncertainty, calculated 
using the standard error statistics of the EQAs. Each of these compo-
nents has similar statistical properties (i.e. they represent the square 
roots of the variances of their respective estimators, and have the 
same MU unit).
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For each MP, a careful consideration was made of the degree of asso-
ciation between the measurand concentration levels, imprecision 
and bias. For those MPs where bias, imprecision or both of them 
were dependent on concentration levels, two or more MU values 
were estimated; otherwise, a single MU was calculated for each MP. 
The long-term IQC results (of the latest 6 months) were used to cal-
culate the imprecision component of uncertainty for each IQC con-
centration level. In cases in which the imprecision values of each 
concentration level were similar, the pooled imprecision was calcu-
lated by taking the square root of the combination of the variances 
of each long-term IQC series of results (eq. 1). Equation 1 represents 
the weighted average of IQCs variance (sQC2), considering the series 
from i = 1 to k IQC levels, each one calculated with the correspond-
ing number of determinations (ni); in particular, when the number 
of determinations ni (used to calculate each sQC2) are the same for 
each IQC level, the equation become equal to the arithmetic mean of 
sQC2. Subsequently, for each MP, the EQA results obtained during the 
survey period 2015–2016 were used to estimate the bias. Only satis-
factory EQAs results were kept, whereas results not complying with 
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established EQA criteria (i.e. results with z-scores > 2 or < − 2) were 
discarded. The approach used was based on feasibility possibilities. 
In order to calculate the bias component the value obtained with the 
reference procedure (reference MPs of higher metrological order) 
was used when available in EQAs, when the results concerning the 
specific diagnostic system failed to show standardization problems, 
or when EQAs control material did not present commutability prob-
lems. Otherwise, the consensus value related to the used diagnostic 
system was employed.
The latest eight EQAs were chosen to calculate both RMSbias 
(eq. 2), and the uncertainty of bias ubias. Equation 2 represents the 
square root of the mean of the squares of bias deviations, where m 
represents the number of EQAs results used (m = 8). Regarding the 
calculation of ubias, initially each standard deviation given for the spe-
cific EQA result was divided by the square root of the number of par-
ticipating laboratories; following the average of these quantities was 
then defined as ubias. However, when EQAs used the median or other 
robust statistical methods to calculate the consensus value, ubias was 
multiplied by 1.25, according to the method for MU calculation speci-
fied in ISO 13528 : 2015 [15].
Finally, the formula in Equation 3 (eq. 3) was used to estimate 
MU, using a coverage factor equal to 2 (k in eq. 3) that was employed 
to adjust MU to a specific level of confidence; a factor of 2 gives a con-
fidence level of 95.4% (the true value probability for Z = 2).
Statistical analyses
The non-parametric Kruskal-Wallis test was used to evaluate dif-
ferences across several groups and p-value were adjusted by 
 Bonferroni’s method for multiple comparisons. Stata v 13.1 (Stata-
corp, College Station, TX, USA) and Microsoft® Excel 2011 for Mac 
( Microsoft® Corporation, Redmond, WA, USA) software were used for 
all the statistical analyses.
Results
The Nordtest, Eurachem, Eurolab and GUM approaches 
were evaluated for their applicability, considering the 
data already available in our laboratory [7, 12–14]. The 
Nord test approach was chosen for estimating MU, as it has 
proved to be adequate for most MPs. A total of 263 MPs 
were studied for MU estimation; Figure 1 summarizes the 
relative percentages for types of sample matrix included 
in the study. Of the MPs evaluated, 39.5% were for serum 
specimens, 35.4% plasma, 9.5% urine, and 11.4% blood; 
as shown in the Figure 1, overall these cases accounted 
for > 95% of the MP types included in the study. MPs were 
subdivided on the basis of four different laboratory areas 
(clinical biochemistry, clinical and molecular biology, 
coagulation and hematology and diagnostic and clinical 
immunology).
Table 1 summarizes the results for MU estimation of 
all the MPs included in the study. The bias component 
Figure 1: Sample types, expressed as percentages of total measure-
ment procedures.
of MU was quantifiable for 190 MPs, but was not calcu-
lated in the remaining 22 MPs due to: a) low number of 
laboratories participating (less than six laboratories, eight 
MPs) precluded a reliable estimate of the consensus value 
related to diagnostic system group; b) lack of standard 
deviations in EQAs reports (two MPs); c) low number of 
EQAs results obtained during the survey period (12 MPs). 
Nor was the bias component of MU considered in the MU 
calculation of 51 MPs because the latter were used mainly 
for monitoring patients; therefore, only the imprecision 
component was chosen for MU estimation.
For a total of 28 MPs, two or more MU values were 
calculated, imprecision and/or bias being dependent 
on concentration levels. Figure 2 shows the contribu-
tion of different components (imprecision, bias, and bias 
uncertainty) on MU estimation, overall and subdivided 
according to matrix types. In addition, a more detailed 
description of some key measurands is also provided in 
Table 2, to indicate the MU information used in the com-
parison. Overall, and more generally for all the matrix 
types evaluated, the results showed that bias uncertainty 
was a minor contributory factor in MU, although in MPs 
using stool samples, the magnitude of this component is 
comparable with that of imprecision and bias. In contrast, 
the bias component of MU represents the most relevant 
contributory factor in blood and plasma samples. For cer-
ebrospinal fluid, serum and urine the contribution of bias 
is not significantly different to the uncertainty contribu-
tion related to the imprecision component.
Discussion
The purpose of medical laboratories is to provide reliable 
information for improving patient health. This goal not 
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Figure 2: Contribution to measurement uncertainty (MU) of impreci-
sion (uimp), bias root mean square error (RMSbias) and bias uncer-
tainty (ubias), expressed as percentages.
Contributions to MU are calculated Overall (considering all the MPs 
with a calculable trueness) or subdividing by matrix types. Bars 
represent the median percentage values. *p < 0.05.
Table 1: Measurement uncertainty (MU) results obtained for all the measurement procedures (MPs) included in the study, subdivided by the 
different laboratory areas.
MU estimation
Laboratory areas  
 
Imprecision 
 
Bias   Total 
tests
  Type of matrices   MU calculated 
for different 
levelsMP used for monitoring 
patients
MPs with 
calculable 
trueness
 
 
EQAs with insufficient statistics
Number  Specifications
Clinical 
biochemistry
  51  136  8  Trueness not included 
as the number of 
participating labs for 
bias estimation was 
limited
  195  Urine (25), blood (5), 
serum (83), plasma 
(72), cerebrospinal 
fluid (8), saliva (1), 
stool (1)
  16
Clinical and 
molecular biology
  0  1  1  MP with EQAs without 
AV standard deviation
  2  Blood (1), stool (1)   1
Coagulation and 
hematology
  0  33  12  MPs with insufficient 
number of EQA results
  45  Plasma (21), blood 
(24)
  11
Diagnostic 
and clinical 
immunology
  0  20  1  MPs with EQAs without 
AV standard deviation
  21  Serum (21)   0
Total   51  190  22    263    28
EQAs, external quality assessment schemes; AV, assigned value.
only entails MPs being fit for their clinical purpose, but 
also laboratories caring about the quality of MPs results, 
using routine evaluation of IQC, participating in profi-
ciency testing or EQAs and comparing their own results 
with those of other laboratories [16]. As MU is an impor-
tant consideration when interpreting test results, it is a 
critical aspect of all MPs [9].
In some recently issued guidelines and studies, MU 
estimation for medical laboratories has been discussed, 
and the applicability of suggested approaches has been 
evaluated against tools already available in medical labo-
ratories for monitoring the quality of test results, such as 
IQC and EQAs results, and focusing on MU components. 
To this end, advantage was taken of the long-term data 
collected for laboratories on IQC and EQAs, which pro-
vided reliable statistics for MU estimation. In fact, ideally 
the bias estimation should be performed by comparing 
results from field methods with reference methods and 
using patients samples to avoid commutability problems. 
However, as suggested by Tran et al. [17] this approach in 
studying bias is not frequently practicable and realistic 
for medical laboratories; in contrast, the determination of 
bias based on an EQAs peer group mean (consensus value) 
could represent a possible and standardized alternative. 
Based on this premise, the Nordtest approach was chosen 
for MU estimation as it was suitable for estimating MU for 
most of the MPs evaluated, although its applicability was 
limited by the presence of sufficient statistics for both IQC 
and EQA results. Furthermore, the Nordtest approach rep-
resented the actual “dispersion of the values that could 
reasonably be attributed to the measurand” as it included 
all the components of MU, namely imprecision, bias and 
uncertainty of bias.
Imprecision data were available for all the 263 
MPs evaluated, whereas the bias component and the 
bias uncertainty obtained from EQAs could not be esti-
mated for some MPs (8.3%). In particular, for two EQAs, 
statistics included only the assigned value, while the 
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distribution statistics (standard deviation or interquar-
tile range) were missing. In these and other situations 
(e.g. where statistical processing of EQAs results does 
not provide reliable data for specific use or the number 
of surveys per year is low, or the number of results 
related to diagnostic system group is low), no calcula-
tion can be made for estimating bias components; other 
approaches are available for this calculation, although 
they involve more complex procedures. The model pro-
posed here for bias estimation appears to be more a prac-
tical solution than a theoretical approach, and further 
studies are advisable in order to define new strategies for 
bias calculation, specifically related to theoretical bias 
references (e.g. previous results, reference intervals and 
clinical decision points). Furthermore, a possible limita-
tion of this study is that it describes an approach for MU 
estimation, rather than evaluating the outcome, that will 
be further investigated.
In conclusion, in this study we provide some usable 
practical procedures regarding the MU estimation for 
a series of MPs, routinely used in medical laboratories. 
In particular, for imprecision component its estimation 
appears to be a reliable estimation of MU if the correct 
interpretation of the lab test result is guaranteed on the 
basis of its clinical purpose. For the bias component, the 
development of a practical solution for including bias 
in MU estimation allowed us to derive a standardized 
approach that considers the source of the bias reference 
and whether and how bias can be calculated, represent-
ing the novelty of this study.
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